Linda-Gail Bekker, who helped prove the drug Lenacapavir’s effectiveness, tells The Independent that $40 doses bring hope – ...

This antiretroviral has shown unprecedented results in HIV prevention, requiring only two injections per year. Its ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

A twice-yearly injection described as the most promising HIV prevention tool in decades is poised to reach millions more ...

Bengaluru: Indian drugmakers Dr Reddy's Laboratories and Hetero Labs said on Wednesday that they will sell generic versions ...

Scientists say the drug stops the virus from replicating inside cells. The landmark deal to provide cheaper antiretroviral ...

Hyderabad-based drugmakers Dr. Reddy’s Laboratories and Hetero Labs have signed separate agreements that will make their generic version of Gilead Sciences’ HIV prevention drug Lenacapavir available ...

Two partnerships will provide millions of people access to what is widely described as the most effective HIV prevention drug ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

A new HIV prevention drug, Lenacapavir, will be made available at a significantly reduced cost in over 100 low-income countries by 2027.

Generics of Gilead Sciences' twice-yearly HIV pre-exposure prophylaxis (PrEP) Yeztugo (lenacapavir) are on the horizon, with ...

No Women on Uganda's 2026 Presidential BallotUganda's Electoral Commission confirmed eight candidates for the 2026 presidential election, narrowing the field from 220 people who had picked nomination ...